We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Novel Flow Cytometry-Based Method Analyzes Heinz Bodies

By LabMedica International staff writers
Posted on 26 Jan 2017
Heinz bodies are inclusions within red blood cells (RBCs) that are composed of denatured hemoglobin molecules and are a highly sensitive indicator of in vivo oxidative stress. More...
Heinz body formation has also been reported in chronic liver disease and α-thalassemia patient.

Historically, light microscopes have been used to visualize specially stained Heinz bodies, which can be seen as spherical inclusions at the peripheries of RBCs. However, microscopic examination of Heinz bodies is time-consuming, labor intensive, and of low sensitivity.

Scientists at the Chulalongkorn University and their associates collected whole-blood samples from patients deficient in Glucose-6-phosphate dehydrogenase (G6PD) and healthy volunteers. The study's G6PD-deficient group included patients who had previously been diagnosed. These subjects were apparently healthy and ranged in age from 25 to 45 and none had ever experienced an acute hemolytic crisis or had experienced fever, inflammation, or infection.

Washed RBCs were incubated in the acetylphenylhydrazine solution at 37 °C. After incubating for one hour, the Heinz bodies were counted under a light microscope at ×100. G6PD enzyme activity was determined using the G6PD assay kit. Enzyme activity was determined using a temperature-regulated spectrophotometer by measuring the change in rate in absorbance at 340 nm. RBCs positive for Heinz bodies were examined using a FACSCanto II cytometer.

The investigators found that RBCs treated with acetylphenylhydrazine formed Heinz bodies and emitted a broad spectrum of fluorescence that could be detected by flow cytometry. The maximum emission of fluorescence was observed at 45 minutes after the incubation with acetylphenylhydrazine. In addition, the fluorescence emitted was stable for at least 72 hours. The flow cytometer could detect the RBCs positive for Heinz bodies even if they made up as little as 0.1% of the total RBC population. Furthermore, the percentage and number, respectively, of RBCs positive for Heinz bodies in G6PD-deficient patients and normal donors exhibited a mean ± standard deviation (SD) of 68.9 ± 27.5 versus 50.9 ± 28.6 and 96,014 ± 35,732 cells/μL versus 74,688 ± 36,514 cells/μL.

The author concluded that Heinz bodies induced by acetylphenylhydrazine emit fluorescence, and this fluorescence could be examined using flow cytometry. Their study suggests the potential use of the developed method to investigate the formation of Heinz bodies in clinical samples. The study was published on January 16, 2017, in the International Journal of Laboratory Hematology.


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Serum Indices Control
Acusera Serum Indices Control
New
Automated Immunoassay Analyzer
SuperFlex™
Automated Clinical Chemistry Analyzer
Envoy 500+
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: WashU Medicine researchers found that dozens of blood proteins shift during Alzheimer’s treatment and may help monitor the effects of the medication. (Image Credit: Matt Miller/WashU Medicine)

Blood Biomarker Patterns Could Support Monitoring of Anti-Amyloid Treatment

Patients with early-stage Alzheimer’s disease may receive anti-amyloid therapy to clear amyloid protein deposits from the brain. These treatments can slow disease progression, but they do not cure the... Read more

Molecular Diagnostics

view channel
Image: University of Florida scientists Hugh Fan, Ph.D., and John Lednicky, Ph.D., led the development of a cost-effective, accurate handheld device capable of simultaneously testing for seven different mosquito-borne viruses. (Image Credit: UF Health photo by Hannah Clark)

Portable Test Differentiates Seven Mosquito-Borne Viruses at Point of Care

Mosquito-borne viral illnesses can present with overlapping symptoms such as fever, joint pain, fatigue, and rash, making them difficult to distinguish without laboratory testing. In these settings, clinicians... Read more

Immunology

view channel
Image: Aptiva utilizes particle-based multi-analyte technology (PMAT) (Photo courtesy of Werfen)

Werfen Expands Automated APS Testing with FDA-Cleared and CE-Marked IgA Reagent

Antiphospholipid syndrome (APS) is an autoimmune disorder associated with thrombosis and pregnancy complications, but its symptoms can overlap with those of other conditions, complicating diagnosis.... Read more

Microbiology

view channel
Image: Each PhAST instrument supports random-access processing of up to four samples simultaneously, delivering a throughput of up to 12 samples per eight-hour shift. (Photo courtesy of PhAST)

FDA Clears Rapid Phenotypic Antimicrobial Susceptibility System for Positive Blood Cultures

Bloodstream infections require prompt treatment, but antimicrobial susceptibility results often lag behind a positive blood culture. Conventional testing can take another 24 to 48 hours after a culture... Read more

Industry

view channel
Image

Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection

Alzheimer’s disease is often identified only after substantial neurodegeneration, partly because current diagnostic pathways are fragmented and difficult to scale. As treatment shifts toward earlier intervention,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.